Who is eligible for clinical trial NCT06453109?

Participants must meet the protocol's inclusion criteria for Opioid Use Disorder. The stated age range is 18 Years to 75 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT06453109 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2024-11-15

Focused Ultrasound for the Complex Patient (NCT06453109)

Towards Treatment of the Complex Patient: Investigations of Low-intensity Focused Ultrasound

🟢 Recruiting Observational / Diagnostic ⚙️ Medical Device Protocol Sponsor: Washington D.C. Veterans Affairs Medical Center

🩺 Plain-English Summary (8th-Grade Level)

The goal of this clinical trial is to to inhibit the anterior insula (AI) with low intensity focused ultrasound (LIFU) to determine the causal role for the AI in pain processing, anxiety, and opiate cue-induced craving. The main question\[s\] it aims to answer are: * the safety and tolerability of LIFU delivered bilaterally to AI compared to sham stimulation in individuals with opiate use disorder (OUD), anxiety, and chronic back pain * the effects of LIFU vs sham on measures of pain processing, anxiety symptoms, and opiate cue-induced craving Participants will undergo anatomical MRI, neurological assessment, clinical assessment and patient query to assess the safety and tolerability of LIFU vs sham.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (9 items).

Location: Washington DC Veterans Affairs Medical Center — Washington D.C., District of Columbia

Age range: 18 Years to 75 Years

🧪 Interventions in This Study

low intensity focused ultrasound (LIFU) (DEVICE)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Males and females aged 18-75 years
Current diagnosis of Chronic Back Pain as defined by pain duration of at least three months, with back pain being an ongoing problem for at least half the days of the last six months.
Have evidence of central sensitization (CS) as measured by the Widespread Pain/Symptom Severity Index (WPSSI) with a score of Widespread Pain Index (WPI) ≥ 7 and Symptom Severity (SS) ≥ 5 or WPI = 3-6 and SS ≥ 9.
Participants must rate pain intensity at 4/10 or greater on the Brief Pain Inventory-Short Form (BPI-SF)
Meet the DSM-5 criteria for current opiate use disorder as diagnosed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.
Be in treatment for OUD including buprenorphine or methadone.
Meet the DSM-5 criteria for a current anxiety disorder: generalized anxiety disorder, post-traumatic stress disorder or social anxiety disorder as diagnosed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition(DSM-5).

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Evidence of neuropathic pain
Current DSM-5 substance use disorder other than OUD, tobacco use disorder
Current DSM-5 diagnosis of schizophrenia or schizo-affective disorder
Pregnant or breastfeeding
Daily use of benzodiazepines or opiates (other than buprenorphine or methadone)
History of seizures, neurologic disorders, including cerebrovascular disease, history of stroke, brain surgery, brain tumor, multiple sclerosis, or neurodegenerative diseases. They will not have history of metastasizing cancers, inflammatory disorder: rheumatoid arthritis, polymyalgia rheumatica, scleroderma, lupus or polymyositis, unintended weight loss of 20 pounds or more in the last year, or cauda equina syndrome.
Ferromagnetic implants or other contraindications for MRI
Unstable medical conditions such as congestive heart failure, unstable angina, poorly controlled arrhythmia active systemic infection end stage renal disease.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Washington DC Veterans Affairs Medical Center — Washington D.C., District of Columbia

📞 Contact the Study Coordinator

Phone: (202) 745-8000

Email: mary.lee3@va.gov

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Opioid Use Disorder

Standard Versus High Dose ED-Initiated Buprenorphine Induction — Oakland, California
Adversity, Brain and Opioid Use Study — Ann Arbor, Michigan
Therapy and Peer Support for Patients Taking Medication for Opioid Use Disorder — Atlantic City, New Jersey
Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD — Charleston, South Carolina
Removing Barriers: Community Partnering for Innovative Solutions to the Opioid Crisis — Ann Arbor, Michigan

Explore by condition: All Opioid Use Disorder clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗